Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial Cancer

Enrique Grande, MD, head of the Medical Oncology Service, head of Clinical Research of the MD Anderson Foundation Spain, MD Anderson Cancer Centre, Madrid, Spain, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Urothelial cancer has a high mutational burden and the more mutations a tumor has, the more the tumor releases tumor antigens, explains Grande. Therefore, according to Grande, the stimulation of the immune system will be better with atezolizumab (Tecentriq) as the checkpoint inhibitor.

The purpose of the IMvigor130 trial is to examine the synergy between chemotherapy plus immunotherapy, says Grande. Chemotherapy is used to release more neoantigens into the microenvironment of the tumor, which may enhance the activity of the immune system in addition to the action of the atezolizumab, concludes Grande.